vs
AUTONATION, INC.（AN）与美敦力（MDT）财务数据对比。点击上方公司名可切换其他公司
美敦力的季度营收约是AUTONATION, INC.的1.3倍（$9.0B vs $6.9B），美敦力净利率更高（15.3% vs 2.5%，领先12.8%），美敦力同比增速更快（6.6% vs -3.9%），美敦力自由现金流更多（$457.0M vs $64.2M），过去两年美敦力的营收复合增速更高（5.3% vs 3.4%）
AutoNation是总部位于美国佛罗里达州劳德代尔堡的汽车零售企业，1996年由韦恩·休伊森创立，最初仅拥有12家门店，目前在全美运营超300个零售网点，提供新车、二手车销售及相关配套服务。
美敦力是全球知名的医疗设备企业，法定及行政总部位于爱尔兰，运营总部设在美国明尼苏达州明尼阿波利斯。2015年集团收购爱尔兰企业柯惠后将注册地迁至爱尔兰，目前业务覆盖超150个国家，员工逾9万名，专注于研发生产各类医疗技术产品及治疗解决方案。
AN vs MDT — 直观对比
营收规模更大
MDT
是对方的1.3倍
$6.9B
营收增速更快
MDT
高出10.6%
-3.9%
净利率更高
MDT
高出12.8%
2.5%
自由现金流更多
MDT
多$392.8M
$64.2M
两年增速更快
MDT
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $6.9B | $9.0B |
| 净利润 | $172.1M | $1.4B |
| 毛利率 | 17.5% | 65.8% |
| 营业利润率 | 4.5% | 18.8% |
| 净利率 | 2.5% | 15.3% |
| 营收同比 | -3.9% | 6.6% |
| 净利润同比 | -7.5% | 8.2% |
| 每股收益（稀释后） | $4.68 | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANMDT
| Q4 25 | $6.9B | $9.0B | ||
| Q3 25 | $7.0B | $8.6B | ||
| Q2 25 | $7.0B | $8.9B | ||
| Q1 25 | $6.7B | $8.3B | ||
| Q4 24 | $7.2B | $8.4B | ||
| Q3 24 | $6.6B | $7.9B | ||
| Q2 24 | $6.5B | $8.6B | ||
| Q1 24 | $6.5B | $8.1B |
净利润ANMDT
| Q4 25 | $172.1M | $1.4B | ||
| Q3 25 | $215.1M | $1.0B | ||
| Q2 25 | $86.4M | $1.1B | ||
| Q1 25 | $175.5M | $1.3B | ||
| Q4 24 | $186.1M | $1.3B | ||
| Q3 24 | $185.8M | $1.0B | ||
| Q2 24 | $130.2M | $654.0M | ||
| Q1 24 | $190.1M | $1.3B |
毛利率ANMDT
| Q4 25 | 17.5% | 65.8% | ||
| Q3 25 | 17.6% | 65.0% | ||
| Q2 25 | 18.3% | 64.8% | ||
| Q1 25 | 18.2% | 66.5% | ||
| Q4 24 | 17.2% | 64.9% | ||
| Q3 24 | 18.0% | 65.1% | ||
| Q2 24 | 17.9% | 64.5% | ||
| Q1 24 | 18.5% | 65.6% |
营业利润率ANMDT
| Q4 25 | 4.5% | 18.8% | ||
| Q3 25 | 5.3% | 16.8% | ||
| Q2 25 | 3.1% | 16.1% | ||
| Q1 25 | 5.0% | 19.9% | ||
| Q4 24 | 4.7% | 19.0% | ||
| Q3 24 | 5.3% | 16.1% | ||
| Q2 24 | 4.2% | 12.3% | ||
| Q1 24 | 5.2% | 18.3% |
净利率ANMDT
| Q4 25 | 2.5% | 15.3% | ||
| Q3 25 | 3.1% | 12.1% | ||
| Q2 25 | 1.2% | 11.8% | ||
| Q1 25 | 2.6% | 15.6% | ||
| Q4 24 | 2.6% | 15.1% | ||
| Q3 24 | 2.8% | 13.2% | ||
| Q2 24 | 2.0% | 7.6% | ||
| Q1 24 | 2.9% | 16.3% |
每股收益（稀释后）ANMDT
| Q4 25 | $4.68 | $1.07 | ||
| Q3 25 | $5.65 | $0.81 | ||
| Q2 25 | $2.26 | $0.81 | ||
| Q1 25 | $4.45 | $1.01 | ||
| Q4 24 | $4.62 | $0.99 | ||
| Q3 24 | $4.61 | $0.80 | ||
| Q2 24 | $3.20 | $0.50 | ||
| Q1 24 | $4.49 | $0.99 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $58.6M | $8.3B |
| 总债务越低越好 | $3.7B | $27.7B |
| 股东权益账面价值 | $2.3B | $48.7B |
| 总资产 | $14.4B | $91.3B |
| 负债/权益比越低杠杆越低 | 1.58× | 0.57× |
8季度趋势，按日历期对齐
现金及短期投资ANMDT
| Q4 25 | $58.6M | $8.3B | ||
| Q3 25 | $97.6M | $8.1B | ||
| Q2 25 | $62.9M | $9.0B | ||
| Q1 25 | $70.5M | $7.9B | ||
| Q4 24 | $59.8M | $8.0B | ||
| Q3 24 | $60.2M | $7.8B | ||
| Q2 24 | $85.9M | $8.0B | ||
| Q1 24 | $60.3M | $8.3B |
总债务ANMDT
| Q4 25 | $3.7B | $27.7B | ||
| Q3 25 | — | $26.2B | ||
| Q2 25 | — | $25.6B | ||
| Q1 25 | $3.1B | $24.0B | ||
| Q4 24 | $2.6B | $24.6B | ||
| Q3 24 | $3.1B | $26.3B | ||
| Q2 24 | $3.1B | $23.9B | ||
| Q1 24 | $3.1B | $24.2B |
股东权益ANMDT
| Q4 25 | $2.3B | $48.7B | ||
| Q3 25 | $2.5B | $47.9B | ||
| Q2 25 | $2.5B | $48.0B | ||
| Q1 25 | $2.4B | $49.4B | ||
| Q4 24 | $2.5B | $48.5B | ||
| Q3 24 | $2.4B | $47.9B | ||
| Q2 24 | $2.2B | $50.2B | ||
| Q1 24 | $2.4B | $51.8B |
总资产ANMDT
| Q4 25 | $14.4B | $91.3B | ||
| Q3 25 | $14.2B | $91.0B | ||
| Q2 25 | $13.6B | $91.7B | ||
| Q1 25 | $13.3B | $90.0B | ||
| Q4 24 | $13.0B | $90.0B | ||
| Q3 24 | $12.9B | $89.7B | ||
| Q2 24 | $12.8B | $90.0B | ||
| Q1 24 | $12.0B | $90.8B |
负债/权益比ANMDT
| Q4 25 | 1.58× | 0.57× | ||
| Q3 25 | — | 0.55× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | 1.29× | 0.49× | ||
| Q4 24 | 1.06× | 0.51× | ||
| Q3 24 | 1.32× | 0.55× | ||
| Q2 24 | 1.43× | 0.48× | ||
| Q1 24 | 1.32× | 0.47× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $150.5M | $925.0M |
| 自由现金流经营现金流 - 资本支出 | $64.2M | $457.0M |
| 自由现金流率自由现金流/营收 | 0.9% | 5.1% |
| 资本支出强度资本支出/营收 | 1.2% | 5.2% |
| 现金转化率经营现金流/净利润 | 0.87× | 0.67× |
| 过去12个月自由现金流最近4个季度 | $-197.5M | $5.2B |
8季度趋势，按日历期对齐
经营现金流ANMDT
| Q4 25 | $150.5M | $925.0M | ||
| Q3 25 | $191.7M | $1.1B | ||
| Q2 25 | $-177.8M | $2.5B | ||
| Q1 25 | $-52.5M | $2.6B | ||
| Q4 24 | $149.8M | $958.0M | ||
| Q3 24 | $-70.0M | $986.0M | ||
| Q2 24 | $-59.6M | $2.8B | ||
| Q1 24 | $294.5M | $2.5B |
自由现金流ANMDT
| Q4 25 | $64.2M | $457.0M | ||
| Q3 25 | $122.8M | $584.0M | ||
| Q2 25 | $-256.8M | $2.1B | ||
| Q1 25 | $-127.7M | $2.1B | ||
| Q4 24 | $83.5M | $554.0M | ||
| Q3 24 | $-151.0M | $466.0M | ||
| Q2 24 | $-147.1M | $2.4B | ||
| Q1 24 | $200.8M | $2.1B |
自由现金流率ANMDT
| Q4 25 | 0.9% | 5.1% | ||
| Q3 25 | 1.7% | 6.8% | ||
| Q2 25 | -3.7% | 23.2% | ||
| Q1 25 | -1.9% | 25.3% | ||
| Q4 24 | 1.2% | 6.6% | ||
| Q3 24 | -2.3% | 5.9% | ||
| Q2 24 | -2.3% | 27.4% | ||
| Q1 24 | 3.1% | 26.3% |
资本支出强度ANMDT
| Q4 25 | 1.2% | 5.2% | ||
| Q3 25 | 1.0% | 5.9% | ||
| Q2 25 | 1.1% | 5.1% | ||
| Q1 25 | 1.1% | 5.7% | ||
| Q4 24 | 0.9% | 4.8% | ||
| Q3 24 | 1.2% | 6.6% | ||
| Q2 24 | 1.4% | 5.0% | ||
| Q1 24 | 1.4% | 4.3% |
现金转化率ANMDT
| Q4 25 | 0.87× | 0.67× | ||
| Q3 25 | 0.89× | 1.05× | ||
| Q2 25 | -2.06× | 2.39× | ||
| Q1 25 | -0.30× | 1.99× | ||
| Q4 24 | 0.80× | 0.75× | ||
| Q3 24 | -0.38× | 0.95× | ||
| Q2 24 | -0.46× | 4.25× | ||
| Q1 24 | 1.55× | 1.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AN
| New Vehicle | $3.4B | 50% |
| Transferred At Point In Time | $1.7B | 24% |
| Parts And Service | $1.2B | 18% |
| Finance And Insurance Net | $369.4M | 5% |
| Transferred Over Time | $221.4M | 3% |
| Other | $3.5M | 0% |
MDT
| Cardiac Rhythm And Heart Failure Division | $1.8B | 20% |
| Surgical Endoscopy | $1.7B | 19% |
| Other | $1.3B | 14% |
| Structural Heart And Aortic Division | $956.0M | 11% |
| Diabetes Group | $757.0M | 8% |
| Specialty Therapies Division | $744.0M | 8% |
| Coronary And Peripheral Vascular Division | $655.0M | 7% |
| Neuromodulation Division | $520.0M | 6% |
| Acute Care Monitoring | $493.0M | 6% |
| IE | $35.0M | 0% |
